FIELD: organic chemistry, medicine, oncology, biochemistry, pharmacology.
SUBSTANCE: invention relates to the development of a method for inhibition in interaction of metalloproteinase 2 with integrin αvβ3 in host cells. Method involves contact of integrin with the amount of compound inhibiting this interaction and represented by the formula (I): wherein each of G1 and G2 represents independently -NH-C(O)-O-R1, -NH-C(O)-O-(CH2)v-(C6H4)-X3, -NH-C(O)-NH-(CH2)v-(C6H4)-X3, -O-C(O)-NH-(CH2)v-(C6H4)-X3, -O-C(O)-O-(CH2)v-(C6H4)-X3 or -NH-C(O)-CH2-(C6H4)-X3; each of Y1 and Y2 represents independently -OH, (C1-C4)-alkyl, (C1-C4)-hydroxyalkyl, (C1-C4)-alkoxy-group, phenyl, benzyl or -NH2; R1 represents (C1-C4)-alkyl; each of X1 and X2 represents independently halogen atom or (C1-C4)-alkoxy-group; X3 represents halogen atom, nitro-group, (C1-C4)-alkyl, (C1-C4)-alkoxy-group or (C1-C4)-perfluoroalkyl; Z represents -C≡C-, -C6H4-, cis-CH=CH-, trans-CH=CH-, cis-CH2-CH=CH-CH2-, trans-CH2-CH=CH-CH2-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, cis-1,4-cyclohexyl or trans-1,4-cyclohexyl; A represents hydrogen atom (H) or a covalent bond; each of m and n represents independently a whole number o or 1; t represents a whole number o or 1; each of p, r and v represents a whole number 1 or 2 and under condition that when A means hydrogen atom (H) then t is 0; when A means a covalent bond then t = 1, and when m = 0 then Y1 represents (C1-C4)-hydroxyalkyl, and when n = o then Y2 represents (C1-C4)-hydroxyalkyl. Also, invention describes a method for apoptosis induction involving administration of abovementioned substance in the therapeutically effective dose.
EFFECT: improved method for tumor inhibition, expanded assortment of antitumor agents.
37 cl, 9 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF TUMOR GROWTH (VARIANTS) | 2001 |
|
RU2276133C2 |
NUCLEIC ACID DELIVERY SYSTEM | 2002 |
|
RU2294192C2 |
PEPTIDE COMPOUNDS | 2005 |
|
RU2393167C2 |
ANTAGONISTS OF VITRONECTIN RECEPTOR, THEIR PREPARING AND APPLICATION | 1997 |
|
RU2198892C2 |
COMBINED THERAPY BY USING PENTAFLUOROBENZENE SULFONAMIDES | 2000 |
|
RU2268054C2 |
HETEROCYCLIC DERIVATIVES OF GLYCYL-BETA-ALANINE AS ANTAGONISTS OF VITRONECTIN | 1999 |
|
RU2215746C2 |
INHIBITORS OF PROTEASES DECOMPOSING AFTER PROLINE | 2002 |
|
RU2345065C2 |
PEPTIDE-BASED COMPOUNDS FOR DIRECTED TRANSPORT TO INTEGRIN RECEPTORS | 2002 |
|
RU2303042C2 |
DIPHOSPHINE AND METAL COMPLEXES | 2006 |
|
RU2408600C2 |
VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
Authors
Dates
2006-02-10—Published
2001-03-27—Filed